DermTech (DMTK) Misses Q2 EPS by 6c

DermTech (NASDAQ: DMTK) reported Q2 EPS of ($0.59), $0.06 worse than the analyst estimate of ($0.53). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $2.85 million.

“DermTech continued to execute on its core business drivers during Q2 by delivering healthy sample volume and revenue growth as we began to emerge from the peak of the pandemic,” said John Dobak, M.D., chief executive officer of DermTech. “Our recent efforts to complete the sales force expansion planning, the start of our in-market beta testing of our telemedicine solution, DermTech ConnectTM, and the initiation of a couple of integrated primary network pilots, enables additional adoption of the DermTech Melanoma Test and lays the commercial foundation for future products and channel expansion.”

For earnings history and earnings-related data on DermTech (DMTK) click here.

You May Also Be Interested In

• Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
• Twilio (TWLO) PT Raised to $320 at Tigress Financial Partners
• CPS Technologies (CPSH) Reports In-Line Q3 EPS